TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20157180
Drug: Ocrelizumab 375
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab 375 mg/m2 (n=16)
Study: 20157180
Drug: Ocrelizumab 375
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab 375 mg/m2 first dose, then 750 mg/m2 (n=16)
Study: 16006914
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg trospium chloride twice daily
Study: 11952288
Drug: Intracutaneous injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneous injections of 100 units of Botulinum toxin A (BTXA) on the more severely affected hand
Study: 8636336
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH (various doses)
Study: 8636336
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH (optimal dose)
Study: 10646895
Drug: L-carnitine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine treatment
Study: 24614759
Drug: F-genotype attenuated
Normalized name: F-15599
DrugBank: F-15599 (DB16936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-genotype attenuated mumps vaccine A (3.5 ± 0.25 logCCID50)
Study: 24614759
Drug: F-genotype attenuated
Normalized name: F-15599
DrugBank: F-15599 (DB16936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-genotype attenuated mumps vaccine B (4.25 ± 0.25 logCCID50)
Study: 24614759
Drug: F-genotype attenuated
Normalized name: F-15599
DrugBank: F-15599 (DB16936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-genotype attenuated mumps vaccine C (5.0 ± 0.25 logCCID50)
Study: 24614759
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control (licensed A-genotype vaccine S79 strain)
Study: 20216563
Drug: Food plus
Normalized name: Cyclinex-1 Medical Food Plus Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food plus micronutrient capsule (MN) containing 15 mg zinc/day
Study: 20216563
Drug: Food supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food supplement
Study: 18381791
Drug: Fulvestrant (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant (250 mg intramuscularly for 12 months)
Study: 12407863
Drug: Proposed treatment
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed treatment scheme including clopidogrel and abciximab
Study: 29044764
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (systolic BP target of <120 mmHg)
Study: 29512468
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (systolic BP target of <120 mmHg) with low baseline SBP (<150 mmHg)
Study: 29044764
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (systolic BP target of <140 mmHg)
Study: 29042830
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg A-GPC
Study: 29042830
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg A-GPC
Study: 29042830
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Caffeine
Study: 24492985
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (OM)/Amlodipine besylate (AM)/Hydrochlorothiazide (HCTZ) 40/10/25 mg
Study: 22806822
Drug: Bupropion 100-150
Normalized name: bupropion hydrochloride 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 100-150 mg/day (100 mg/day for <30 kg and 150 mg/day for >30 kg)
Study: 22806822
Drug: Methylphenidate 20-30
Normalized name: methylphenidate hydrochloride 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 20-30 mg/day
Study: 9783884
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no flow modulator)
Study: 2648763
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution with sodium concentration of 35 mmol/l and dextrose of 200 mmol/l
Study: 2648763
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution with sodium concentration of 50 mmol/l and dextrose of 111 mmol/l
Study: 2648763
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution with sodium concentration of 90 mmol/l and dextrose of 110 mmol/l
Study: 27807039
Drug: Interviewer-administered Automated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administered Automated Multiple-Pass Method (AMPM) recall
Study: 10948025
Drug: Homoeopathy (30c
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homoeopathy (30c preparation of principal inhalant allergen)
Study: 26819104
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with intravenous rehydration
Study: 24516621
Drug: Diet (D)
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet (D) treatment
Study: 24516621
Drug: Exercise (E)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise (E) treatment
Study: 21471562
Drug: ChemoEd intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ChemoEd intervention (DVD, question-prompt list, self-care information, education consultation ≥24 h before first treatment, telephone follow-up 48 h after first treatment, face-to-face review immediately before second treatment)
Study: 2466846
Drug: Antithrombin III
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin III and low-dose heparin
Study: 2466846
Drug: Antithrombin III
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin III and low-dose heparin (in cemented prosthesis group)
Study: 20203546
Drug: lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 1.5 mg/kg and esmolol 1.0 mg/kg
Study: 11960947
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1,500 mg/day)
Study: 9534832
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg daily) for 1 week
Study: 9534832
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg daily) for 3 weeks
Study: 9534832
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg daily) for 8 weeks in depressed patients
Study: 202906
Drug: Polyc chemotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyc chemotherapy, high-dosage vitamin-A treatment, Endoxan, immunotherapy, and proteolytic enzymes in 5 combinations of therapy
Study: 16948122
Drug: Postoperative interferon‐α
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative interferon‐α therapy (Group 1)
Study: 16948122
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative interferon‐α therapy (Group 2)
Study: 11318053
Drug: Unintentional contributions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unintentional contributions to nonspecific preparation
Study: 9135342
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.5% bupivacaine
Study: 7931470
Drug: High-dose etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose etoposide and cisplatin (EP)
Study: 7931470
Drug: Standard-dose etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-dose etoposide and cisplatin (EP)
Study: 7931470
Drug: Nonrandomized standard-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonrandomized standard-dose therapy
Study: 2902738
Drug: CQP 201-403
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQP 201-403 (0.01 mg)
Study: 2902738
Drug: CQP 201-403
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQP 201-403 (0.02 mg)
Study: 2902738
Drug: CQP 201-403
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQP 201-403 (0.03 mg)
Study: 30645844
Drug: Yiqi Huaju
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Huaju Recipe (YHR) + routine Western drugs
Study: 30645844
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + routine Western drugs
Study: 26603252
Drug: Iron pyrophosphate
Normalized name: prenatal vitamins no.113/iron pyrophosphate/levomefolate 4.5 mg iron-1 mg ORAL TABLET,CHEWABLE
DrugBank: Ferric pyrophosphate (DB09147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron pyrophosphate (approximately 1 mg/kg) daily until 9 months of age
Study: 26603252
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily until 9 months of age
Study: 20946752
Drug: Standard individual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard individual cognitive behavioral therapy (CBT) for alcohol use disorders
Study: 20946752
Drug: Alcohol behavioral
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol behavioral couple therapy
Study: 20946752
Drug: Blended individual
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended individual CBT and alcohol behavioral couple therapy
Study: 15246968
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg oral solution of GI181771X
Study: 15246968
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg oral solution of GI181771X
Study: 15246968
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg oral solution of GI181771X
Study: 15246968
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg tablet of GI181771X
Study: 11167667
Drug: Inogatran (thrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inogatran (thrombin inhibitor) administered intravenously; specific dosage and duration not mentioned.
Study: 9626201
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg intravenously every 3 to 4 weeks)
Study: 7881452
Drug: Analgesic plus
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic plus caffeine (C)
Study: 7881452
Drug: Analgesic alone
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic alone (A)
Study: 3295599
Drug: Defibrotide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (400 mg b.i.d. by IV route)
Study: 3295599
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin (5000 I.U. t.i.d. s.c.)
Study: 3295599
Drug: Defibrotide and
Normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Defibrotide and Calcium heparin
Study: 30072191
Drug: Nab-paclitaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel (100 mg/m2)
Study: 3664330
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg twice daily)
Study: 26739683
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 mg three times daily)
Study: 26739683
Drug: Rifampicin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (600 mg once daily)
Study: 9165323
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of full fat milk
Study: 9165323
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of still mineral water
Study: 7956714
Drug: Pentoxifylline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (300 mg/day)
Study: 3658570
Drug: Taurine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (30 mg/kg/d)
Study: 23601143
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics therapy (IVAT) for exacerbation, duration: 14 days.
Study: 19325192
Drug: Nicorandil treatment
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil treatment
Study: 16340944
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (1.9 g/kg BW)
Study: 16340944
Drug: Normal-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-protein diet (1.3 g/kg BW)
Study: 21423028
Drug: Irbesartan (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (300 mg/d)
Study: 11130772
Drug: cilazapril (C),
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril (C), 2.5 mg once daily
Study: 16195905
Drug: Oral nystatin
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nystatin (3x10(6) U per day)
Study: 12860576
Drug: Eplerenone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (50 mg/d, titrated to max 200 mg)
Study: 12860576
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 mg/d, titrated to max 10 mg)
Study: 10583711
Drug: Deoxycholic acid
Normalized name: Deoxycholic Acid
DrugBank: Deoxycholic acid (DB03619)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deoxycholic acid (DCA) 750 mg day‐1 for 3 weeks
Study: 9522686
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: prepared surfaces were left unprotected after preparation
Study: 2060527
Drug: Pyrimethamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrimethamine (50 mg/day) plus Clindamycin (2.4 g/day)
Study: 2060527
Drug: Pyrimethamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrimethamine (50 mg/day) and Sulfadiazine (4.0 g/day)
Study: 6416698
Drug: oral pyridoxine
Normalized name: pyridoxine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral pyridoxine
Study: 31755526
Drug: Chimeric Yellow
Normalized name: yellow OB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine (CYD‐TDV) on an accelerated dosing schedule (months 0, 2, and 6)
Study: 31755526
Drug: Chimeric Yellow
Normalized name: yellow OB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine (CYD‐TDV) given concurrently with Japanese encephalitis (JE) vaccine
Study: 31755526
Drug: Chimeric Yellow
Normalized name: yellow OB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine (CYD‐TDV)
Study: 22284441
Drug: Baseline eGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline eGFR > 40 mL/min/1.73 m2 and urine protein‐creatinine ratio < 0.22 g/g
Study: 15126520
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at 0.0125 mg/kg.d, increased to 0.025 mg/kg.d as tolerated, or decreased to 0.00625 mg/kg.d for 12 months
Study: 8036820
Drug: Intradermal hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal hepatitis A vaccine (0.1 ml each, three doses)
Study: 8036820
Drug: Intramuscular hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular hepatitis A vaccine (control group)
Study: 2659740
Drug: VMCP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMCP chemotherapy alone
Study: 26050967
Drug: V0162 (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: V0162 (1600 μg)
Study: 23456567
Drug: Non-aspirin antiplatelets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-aspirin antiplatelets
Study: 23456567
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator therapy (IV-tPA)
Study: 21480976
Drug: Topical phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical phenytoin dressing
Study: 18049795
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg (Group B)
Study: 18049795
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg plus tirofiban (Group C)
Study: 12755777
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded FRIALIT-2(R) implants
Study: 12755777
Drug: Non-loaded implants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-loaded implants
Study: 8797143
Drug: Irbesartan 10
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan 10 mg and above
Study: 8797143
Drug: Irbesartan (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (various doses: 1, 5, 10, 25, 50, and 100 mg)
Study: 1480537
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg trandolapril
Study: 29696916
Drug: Lotensin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotensin (10 mg, once a day)
Study: 27170340
Drug: Basiliximab (IL2Ra)
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab (IL2Ra) 20 mg on Day 0 and Day 4
Study: 27170340
Drug: Rabbit antithymocyte
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabbit antithymocyte globulin (rATG) 1.0 mg/kg/day from Day 0 to Day 4
Study: 24124716
Drug: Furosemide 5-40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 5-40 mg injection in standard group (CVP < 8 mm Hg)
Study: 18194332
Drug: Mouthwash and
Normalized name: SODIUM FLUORIDE 2.4 mg in 1 g DENTAL GEL, DENTIFRICE [AIM TARTAR CONTROL Plus Mouthwash and Whitening]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash and oral gel containing lactoperoxidase, lactoferrin, and lysozyme
Study: 16600923
Drug: Dairy products
Normalized name: Food - Dairy Products, Whey, Cow's Milk
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy products enriched with cis-9,trans-11 CLA (1.421 g/d)
Study: 16600923
Drug: Control dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control dairy products (0.151 g/d CLA)
Study: 9348572
Drug: Pelvic radiation
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic radiation therapy plus fluorouracil (5-FU)-based chemotherapy
Study: 9348572
Drug: Pre- and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre- and postoperative bolus 5-FU/leucovorin combined-modality therapy
Study: 9348572
Drug: Tegafur and
Normalized name: Tegafur and uracil only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegafur and uracil (UFT) with oral leucovorin plus pre- or postoperative radiation therapy
Study: 8446442
Drug: Lidocaine (10‐16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (10‐16 mg)
Study: 23161117
Drug: Radiotherapy (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (with or without chemotherapy)
Study: 19080093
Drug: Alprostadil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprostadil (10 ng/ml added into the prime solution and continuous pump infusion of 10 ng/kg/min via central vein until the end of operation)
Study: 19080093
Drug: Ulinastatin (20,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (20,000 U/kg divided into several doses added into the prime solution)
Study: 19080093
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Alprostadil and Ulinastatin (according to the above protocols)
Study: 14570791
Drug: Bupivacaine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 8 mg + sufentanil 2.5 microg
Study: 14570791
Drug: Levobupivacaine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 8 mg + sufentanil 2.5 microg
Study: 14570791
Drug: Ropivacaine 12
Normalized name: CLONIDINE 0.04MG/KETOROLAC 15MG/ROPIVACAINE 123MG/50ML INJ SYRIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 12 mg + sufentanil 2.5 microg
Study: 1403459
Drug: Oral gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gentamicin
Study: 29275332
Drug: Bimekizumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab (240 mg/160 mg/160 mg; 80 mg/40 mg/40 mg; 160 mg/80 mg/80 mg and 560 mg/320 mg/320 mg)
Study: 11740317
Drug: LAIV (live
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAIV (live attenuated influenza vaccine)
Study: 23210417
Drug: Control chewing
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control chewing gum (sugar-free, without active agents)
Study: 15837660
Drug: Cryoanalgesia (L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryoanalgesia (L group, n=20)
Study: 28933798
Drug: Warfarin 10
Normalized name: warfarin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 10 mg
Study: 11452703
Drug: Warfarin 10
Normalized name: warfarin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 10 mg plus Vitamin K 10 mg
Study: 9610586
Drug: Microwave treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microwave treatment (n = 125)
Study: 9610586
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (n = 44)
Study: 7528584
Drug: HHES (hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: HHES (hypertonic saline hydroxyethyl starch solution) 4 ml.kg‐1
Study: 3228576
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) albuterol 8 mg tablet every 12 h for 8 days
Study: 3228576
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) albuterol 4 mg tablet every 6 h for 8 days
Study: 3228576
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) albuterol